Javascript must be enabled to continue!
Multivisceral central pancreatectomy for pancreatic neuroendocrine tumor
View through CrossRef
Abstract
Introduction
Central pancreatectomy (CP) is considered a viable alternative to subtotal distal pancreatectomy, for lesions involving the neck or proximal pancreatic body. Multivisceral central pancreatectomy (MVCP) for locally advanced tumors of the pancreatic body remains unreported.
Presentation of case
We hereby report a case of locally advanced pancreatic neuroendocrine tumor (NET) with gastric involvement. The patient underwent successful central pancreatectomy with subtotal gastrectomy for locally advanced NET of the pancreas. In the follow up period, relevant complications like pancreatic insufficiency or pancreatic fistula were not encountered. The patient is doing well more than ten months after resection.
Discussion
A MVCP can be considered in patients with limited pancreatic involvement, as long as sufficient pancreatic parenchyma can be preserved. Additional organ involvement mandating resection should not be considered a contra indication to this procedure. With careful surgical planning and meticulous technique, risk of post operative complications after MVCP can be minimized with added benefit of long term endocrine and exocrine integrity.
Conclusions
CP is a viable alternative and can be performed with adjacent organ resection, with acceptable post operative outcomes.
Highlights
Ovid Technologies (Wolters Kluwer Health)
Title: Multivisceral central pancreatectomy for pancreatic neuroendocrine tumor
Description:
Abstract
Introduction
Central pancreatectomy (CP) is considered a viable alternative to subtotal distal pancreatectomy, for lesions involving the neck or proximal pancreatic body.
Multivisceral central pancreatectomy (MVCP) for locally advanced tumors of the pancreatic body remains unreported.
Presentation of case
We hereby report a case of locally advanced pancreatic neuroendocrine tumor (NET) with gastric involvement.
The patient underwent successful central pancreatectomy with subtotal gastrectomy for locally advanced NET of the pancreas.
In the follow up period, relevant complications like pancreatic insufficiency or pancreatic fistula were not encountered.
The patient is doing well more than ten months after resection.
Discussion
A MVCP can be considered in patients with limited pancreatic involvement, as long as sufficient pancreatic parenchyma can be preserved.
Additional organ involvement mandating resection should not be considered a contra indication to this procedure.
With careful surgical planning and meticulous technique, risk of post operative complications after MVCP can be minimized with added benefit of long term endocrine and exocrine integrity.
Conclusions
CP is a viable alternative and can be performed with adjacent organ resection, with acceptable post operative outcomes.
Highlights.
Related Results
Risk Factors of Pancreatic Fistula in Distal Pancreatectomy Patients
Risk Factors of Pancreatic Fistula in Distal Pancreatectomy Patients
Introduction.Benign and malignant lesions of the pancreas located at the body and tail of the pancreas are managed by the standard procedure of distal pancreatectomy (DP). The mort...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
[68Ga]-DOTATOC PET/CT Volumetric Parameters Reflect Metastatic Potential in Pancreatic Neuroendocrine Tumors
[68Ga]-DOTATOC PET/CT Volumetric Parameters Reflect Metastatic Potential in Pancreatic Neuroendocrine Tumors
Background: [68Ga]-DOTATOC PET/CT is a valuable technique for identifying neuroendocrine tumors overexpressing somatostatin receptors; however, its diagnostic and prognostic utilit...
HPB SO15 - Developing protocol for managing diabetes after Distal pancreatectomy
HPB SO15 - Developing protocol for managing diabetes after Distal pancreatectomy
Abstract
Background
The incidence of new-onset diabetes mellitus (NODM) has been reported to be 18% to 39% after pancreaticoduod...
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract
Pancreatic adenocarcinoma (PDAC) remains one of the most lethal cancers today and is expected to be the second cause of cancer death in the coming decade. M...
Laparoscopic total pancreatectomy for multiple endocrine neoplasia type 1 syndrome‐associated multifocal, non‐functioning pancreatic neuroendocrine tumor: A case report
Laparoscopic total pancreatectomy for multiple endocrine neoplasia type 1 syndrome‐associated multifocal, non‐functioning pancreatic neuroendocrine tumor: A case report
AbstractPancreatic neuroendocrine tumors are rare, accounting for less than 3% of all pancreatic tumors. Although laparoscopic pancreas‐preserving surgery for managing sporadic pan...
21 cases of laparoscopic central pancreatectomy
21 cases of laparoscopic central pancreatectomy
Abstract
Objective: To investigate the experience of laparoscopic central pancreatectomy.
Methods: The perioperative data of 21 patients who underwent laparoscopiccentral p...
Abstract 1603: Intra-pancreatic fat promotes the progression of PDAC by activating thermogenesis
Abstract 1603: Intra-pancreatic fat promotes the progression of PDAC by activating thermogenesis
Abstract
Background: The presence of minimal intra-pancreatic fat deposition (IPFD) in the healthy human pancreas has been demonstrated in numerous studies. But exce...

